Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04604132 · ClinicalTrials.gov registry record · Phase 1
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
A Phase 1 study, sponsored by Basilea Pharmaceutica.
- Terminated
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT04604132 is a Phase 1 study that was terminated before completion, run by Basilea Pharmaceutica. The registered enrollment target is 47 participants.
The verdict
NCT04604132, a Phase 1 study, was terminated before completion, sponsored by Basilea Pharmaceutica.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the efficacy of derazantinib monotherapy or derazantinib in combination with paclitaxel and ramucirumab in patients with gastric adenocarcinoma (GAC) i.e. with human epidermal growth factor receptor 2 (HER2)-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring fibroblast growth factor receptor 2 (FGFR2) genetic aberrations (GA).
Interventions
- DRUG Derazantinib
- DRUG Derazantinib-paclitaxel-ramucirumab combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2020-10-06 |
| Est. Completion | 2022-11-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04604132
The ClinicalTrials.gov registry entry for NCT04604132 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Basilea Pharmaceutica, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Derazantinib is the first listed.
NCT04604132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04604132 about?
NCT04604132 is a clinical study titled "Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma". The purpose of this study was to evaluate the efficacy of derazantinib monotherapy or derazantinib in combination with paclitaxel and ramucirumab in patients with gastric adenocarcinoma (GAC) i.e. with human epidermal growth factor receptor 2 (HER2)-negative adenocarcinoma of the stomach or gastro-e...
What is the current status of trial NCT04604132?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2020-10-06. Estimated completion is 2022-11-21.
What interventions are being tested in trial NCT04604132?
The interventions under investigation include: Derazantinib (DRUG), Derazantinib-paclitaxel-ramucirumab combination (DRUG).
Who is sponsoring clinical trial NCT04604132?
This trial is sponsored by Basilea Pharmaceutica, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.